Skip to main content

Table 3 Patients with poorly controlled hypertension, dyslipidemia, or diabetes mellitus, who had subsequent therapy modifications within a 6-months or 12 months-period

From: Clinically relevant quality measures for risk factor control in primary care: a retrospective cohort study

 

Patients with poorly controlled hypertension

Patients with poorly controlled dyslipidemia

Patients with poorly controlled diabetes mellitus

 

6 Months

12 Months

6 Months

12 Months

6 Months

12 Months

 

n

%

n

%

n

%

n

%

n

%

n

%

Appropriate clinical action

211

54.0

240

61.4

67

29.0

87

37.7

46

78.0

50

84.7

Any therapy modification

193

49.4

238

60.9

55

23.8

77

33.3

44

74.6

50

84.7

Increase class

121

30.9

153

39.1

43

18.6

64

27.7

26

44.1

30

50.8

Increase dose

103

26.3

135

34.5

15

6.5

23

10.0

31

52.5

36

61.0

Switch class

30

7.7

49

12.5

0

0.0

2

0.9

6

10.2

10

16.9

Several modifications

55

14.1

88

22.5

3

1.3

11

4.8

19

32.2

26

44.1

Return to control WO modification

18

4.6

2

0.5

12

5.2

10

4.3

2

3.4

0

0.0

Inappropriate clinical action

180

46.0

151

38.6

164

71.0

144

62.3

13

22.0

9

15.3

No modification, return to near control

25

6.4

9

2.3

38

16.5

27

11.7

1

1.7

3

5.1

No modification, no return

120

30.7

134

34.3

40

17.3

40

17.3

7

11.9

2

3.4

No measurement, no modification

35

9.0

8

2.0

86

37.2

77

33.3

5

8.5

4

6.8

  1. LDL = low-density lipoprotein. A switch to different drug class was counted when a new class of medication for the condition was added, but the total number of drug classes remained the same. Categories of control with levels of control, near and poor control for hypertension, dyslipidemia and diabetes mellitus are based on N. Rodondi et al. [5]. This category includes patients without visit or measurements.